Susceptibility-Related Cytokine Panel for Prediction of Polygonum multiflorum-Induced Hepatotoxicity in Humans

References

• Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354(7):731–739. doi:10.1056/NEJMra052270
   PubMed Web of Science ®Google Scholar
• Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950–966; quiz 967. doi:10.1038/ajg.2014.131
   PubMed Web of Science ®Google Scholar
• Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol. 2015;63(2):503–514. doi:10.1016/j.jhep.2015.04.016
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Bjornsson ES. Drug-induced liver injury - types and phenotypes. N Engl J Med. 2019;381(3):264–273. doi:10.1056/NEJMra1816149
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Chalasani N, Björnsson ES, et al. Drug-induced liver injury. Nat Rev Dis Primers. 2019;5(1):58. doi:10.1038/s41572-019-0105-0
   PubMed Web of Science ®Google Scholar
• Björnsson E. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther. 2010;32(1):3–13. doi:10.1111/j.1365-2036.2010.04320.x
   PubMed Web of Science ®Google Scholar
• Urban TJ, Nicoletti P, Chalasani N, et al. Minocycline hepatotoxicity: clinical characterization and identification of HLA-B*35:02 as a risk factor. J Hepatol. 2017;67(1):137–144. doi:10.1016/j.jhep.2017.03.010
   PubMed Web of Science ®Google Scholar
• Nicoletti P, Werk AN, Sawle A, et al. HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury. Pharmacogenet Genomics. 2016;26(5):218–224. doi:10.1097/FPC.0000000000000209
   PubMed Web of Science ®Google Scholar
• Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41(7):816–819. doi:10.1038/ng.379
   PubMed Web of Science ®Google Scholar
• Aithal GP, Ramsay L, Daly AK, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology. 2004;39(5):1430–1440. doi:10.1002/hep.20205
   PubMed Web of Science ®Google Scholar
• Kobayashi E, Kobayashi M, Tsuneyama K, Fukami T, Nakajima M, Yokoi T. Halothane-induced liver injury is mediated by interleukin-17 in mice. Toxicol Sci. 2009;111(2):302–310. doi:10.1093/toxsci/kfp165
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Higuchi S, Mizuno K, et al. Interleukin-17 is involved in alpha-naphthylisothiocyanate-induced liver injury in mice. Toxicology. 2010;275(1–3):50–57. doi:10.1016/j.tox.2010.05.011
   PubMed Web of Science ®Google Scholar
• Higuchi S, Kobayashi M, Yoshikawa Y, et al. IL-4 mediates dicloxacillin-induced liver injury in mice. Toxicol Lett. 2011;200(3):139–145. doi:10.1016/j.toxlet.2010.11.006
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Higuchi S, Ide M, et al. Th2 cytokine-mediated methimazole-induced acute liver injury in mice. J Appl Toxicol. 2012;32(10):823–833. doi:10.1002/jat.2731
   PubMed Web of Science ®Google Scholar
• Poulsen KL, Olivero-Verbel J, Beggs KM, Ganey PE, Roth RA. Trovafloxacin enhances lipopolysaccharide-stimulated production of tumor necrosis factor-α by macrophages: role of the DNA damage response. J Pharmacol Exp Ther. 2014;350(1):164–170. doi:10.1124/jpet.114.214189
   PubMed Web of Science ®Google Scholar
• Roth RA, Maiuri AR, Ganey PE. Idiosyncratic drug-induced liver injury: is drug-cytokine interaction the linchpin? J Pharmacol Exp Ther. 2017;360(2):461–470. doi:10.1124/jpet.116.237578
   PubMed Web of Science ®Google Scholar
• Roth RA, Ganey PE. Animal models of idiosyncratic drug-induced liver injury–current status. Crit Rev Toxicol. 2011;41(9):723–739. doi:10.3109/10408444.2011.575765
   PubMed Web of Science ®Google Scholar
• Jennings JJ, Mandaliya R, Nakshabandi A, Lewis JH. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies. Expert Opin Drug Metab Toxicol. 2019;15(3):231–244. doi:10.1080/17425255.2019.1574744
   PubMed Web of Science ®Google Scholar
• Wang J, Ma Z, Niu M, et al. Evidence chain-based causality identification in herb-induced liver injury: exemplification of a well-known liver-restorative herb Polygonum multiflorum. Front Med. 2015;9(4):457–467. doi:10.1007/s11684-015-0417-8
   PubMed Web of Science ®Google Scholar
• Tu C, He Q, Li CY, et al. Susceptibility-related factor and biomarkers of dietary supplement polygonum multiflorum-induced liver injury in rats. Front Pharmacol. 2019;10:335. doi:10.3389/fphar.2019.00335
   PubMed Web of Science ®Google Scholar
• He LZ, Yin P, Meng YK, et al. Immunological synergistic mechanisms of trans-/cis-stilbene glycosides in Heshouwu-related idiosyncratic liver injury. Sci Bull. 2017;62(11):748–751. doi:10.1016/j.scib.2017.04.020
   PubMed Web of Science ®Google Scholar
• Yang WN, Pang LL, Zhou JY, et al. Single-nucleotide polymorphisms of HLA and Polygonum multiflorum-induced liver injury in the Han Chinese population. World J Gastroenterol. 2020;26(12):1329–1339. doi:10.3748/wjg.v26.i12.1329
   PubMed Web of Science ®Google Scholar
• Li C, Rao T, Chen X, et al. HLA-B*35:01 allele is a potential biomarker for predicting polygonum multiflorum-induced liver injury in humans. Hepatology. 2019;70(1):346–357. doi:10.1002/hep.30660
   PubMed Web of Science ®Google Scholar
• Xiao XH, Li XH, Zhu Y, et al. Guideline for diagnosis and treatment of herb-induced liver injury. Zhongguo Zhong Yao Za Zhi. 2016;07:1165–1172.
   Google Scholar
• Zhang L, Niu M, Wei AW, et al. Risk profiling using metabolomic characteristics for susceptible individuals of drug-induced liver injury caused by Polygonum multiflorum. Arch Toxicol. 2020;94(1):245–256. doi:10.1007/s00204-019-02595-3
   PubMed Web of Science ®Google Scholar
• Meng YK, Li CY, Li RY, et al. Cis-stilbene glucoside in Polygonum multiflorum induces immunological idiosyncratic hepatotoxicity in LPS-treated rats by suppressing PPAR-gamma. Acta Pharmacol Sin. 2017;38(10):1340–1352. doi:10.1038/aps.2017.32
   PubMed Web of Science ®Google Scholar
• Li CY, He Q, Gao D, et al. Idiosyncratic drug-induced liver injury linked to Polygonum multiflorum: a case study by pharmacognosy. Chin J Integr Med. 2017;23(8):625–630. doi:10.1007/s11655-017-2543-9
   PubMed Web of Science ®Google Scholar
• Li C, Niu M, Bai Z, et al. Screening for main components associated with the idiosyncratic hepatotoxicity of a tonic herb, Polygonum multiflorum. Front Med. 2017;11(2):253–265. doi:10.1007/s11684-017-0508-9
   PubMed Web of Science ®Google Scholar
• Dambach DM, Durham SK, Laskin JD, Laskin DL. Distinct roles of NF-kappaB p50 in the regulation of acetaminophen-induced inflammatory mediator production and hepatotoxicity. Toxicol Appl Pharmacol. 2006;211(2):157–165. doi:10.1016/j.taap.2005.06.024
   PubMed Web of Science ®Google Scholar
• Dong Z, Zhang J, Sun R, Wei H, Tian Z. Impairment of liver regeneration correlates with activated hepatic NKT cells in HBV transgenic mice. Hepatology. 2007;45(6):1400–1412. doi:10.1002/hep.21597
   PubMed Web of Science ®Google Scholar
• Brooling JT, Campbell JS, Mitchell C, Yeoh GC, Fausto N. Differential regulation of rodent hepatocyte and oval cell proliferation by interferon gamma. Hepatology. 2005;41(4):906–915. doi:10.1002/hep.20645
   PubMed Web of Science ®Google Scholar